scispace - formally typeset
Journal ArticleDOI

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Reads0
Chats0
TLDR
Ramucirumab is the first biological treatment given as a single drug that has survival benefits in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma progressing after first-line chemotherapy, and validate VEGFR-2 signalling as an important therapeutic target in advanced Gastric cancer.
About
This article is published in The Lancet.The article was published on 2014-01-04. It has received 1728 citations till now. The article focuses on the topics: Ramucirumab & Placebo.

read more

Citations
More filters
Journal ArticleDOI

Comprehensive molecular characterization of gastric adenocarcinoma

Adam J. Bass, +257 more
- 11 Sep 2014 - 
TL;DR: A comprehensive molecular evaluation of 295 primary gastric adenocarcinomas as part of The Cancer Genome Atlas (TCGA) project is described and a molecular classification dividing gastric cancer into four subtypes is proposed.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines

TL;DR: Lymphedema is a common complication after treatment for breast cancer and factors associated with increased risk of lymphedEMA include extent of axillary surgery, axillary radiation, infection, and patient obesity.
References
More filters
Journal ArticleDOI

Global cancer statistics

TL;DR: A substantial proportion of the worldwide burden of cancer could be prevented through the application of existing cancer control knowledge and by implementing programs for tobacco control, vaccination, and early detection and treatment, as well as public health campaigns promoting physical activity and a healthier dietary intake.
Journal ArticleDOI

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

TL;DR: A model by which a combined assessment of all existing lesions, characterized by target lesions and nontarget lesions, is used to extrapolate an overall response to treatment is proposed, which is largely validated by the Response Evaluation Criteria in Solid Tumors Group and integrated into the present guidelines.
Journal ArticleDOI

Angiogenesis in cancer and other diseases

TL;DR: Pathological angiogenesis is a hallmark of cancer and various ischaemic and inflammatory diseases and integrated understanding is leading to the development of a number of exciting and bold approaches to treat cancer and other diseases, but owing to several unanswered questions, caution is needed.
Related Papers (5)

Comprehensive molecular characterization of gastric adenocarcinoma

Adam J. Bass, +257 more
- 11 Sep 2014 -